Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27608848 | 0.87 | ALDH1A1 (0.48) | TSHRCYP1A2ALDH1A1MEN1KMT2A | |
| SCHEMBL5595483 | 0.87 | PTPN1 (0.51) | TSHRCYP1A2ALDH1A1MEN1KMT2A | |
| SCHEMBL3096665 | 0.83 | ALDH1A1 (0.55) | TSHRCYP1A2ALDH1A1MEN1KMT2A | |
| SCHEMBL10668707 | 0.81 | ALDH1A1 (0.51) | TSHRCYP1A2ALDH1A1MEN1KMT2A | |
| SCHEMBL258742 | 0.81 | ALDH1A1 (0.51) | TSHRCYP1A2ALDH1A1MEN1KMT2A | |
| SCHEMBL258592 | 0.81 | ALDH1A1 (0.51) | TSHRCYP1A2ALDH1A1MEN1KMT2A | |
| SCHEMBL10687014 | 0.79 | ALDH1A1 (0.54) | TSHRCYP1A2ALDH1A1MEN1KMT2A | |
| SCHEMBL43104 | 0.79 | ALPI (0.51) | TSHRCYP1A2ALDH1A1 | |
| SCHEMBL8977587 | 0.79 | ALPI (0.51) | TSHRCYP1A2ALDH1A1 | |
| SCHEMBL8986743 | 0.79 | POLB (0.51) | TSHRALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7301049-B2 | Photolabile esters and their uses | THE INSTITUTE OF CANCER RESEARCH (GB) | 2007-11-27 | — | — | US | disclosed |
| US-20040242653-A1 | Photolabile esters and their uses | THE INSTITUTE OF CANCER RESEARCH (GB) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242653-A1 | Photolabile esters and their uses | DIMT1, DCTD, DTYMK | TSHR 1938/4885CYP1A2 4649/4885ALDH1A1 2920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.